Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.06.2022 | Case report

Azacitidine/venetoclax

Lack of efficacy: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wang B-R, et al. A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports. Frontiers in Oncology 11: 797941, 9 Dec 2021. Available from: URL: http://www.frontiersin.org/Oncology/about Wang B-R, et al. A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports. Frontiers in Oncology 11: 797941, 9 Dec 2021. Available from: URL: http://​www.​frontiersin.​org/​Oncology/​about
Metadaten
Titel
Azacitidine/venetoclax
Lack of efficacy: 3 case reports
Publikationsdatum
01.06.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-16395-6

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Antineoplastics

Case report

Tozinameran

Case report

Multiple drugs